Heartflow stock surges 35.7% on raised 2026 revenue guidance

Heartflow's stock rally reflects investor confidence in both the company's near-term execution and its long-term trajectory. The 48% year-over-year revenue growth in Q2 to $64.1 million demonstrates strong market demand for its AI-powered coronary diagnostics platform, which addresses a significant medical need—coronary artery disease is the leading cause of death worldwide. What matters as much to investors is the company's path to profitability: adjusted gross margin expanded 7.7 percentage points year-over-year to 83.3%, while the adjusted operating loss contracted by nearly one-third, from $11.5 million to $7.9 million. This combination of revenue acceleration and improving unit economics suggests Heartflow's business model is scaling efficiently.

The company's decision to raise its full-year 2026 guidance—from 29–32% growth to 40–42%—signals that management sees durable demand and has confidence in its ability to convert that demand into revenue. Equally important, the lifted adjusted gross margin target to 82% reinforces management's expectation that the company will continue to improve profitability as it scales. CEO John Farquhar's statement about "record gross margin and improving operating leverage" reflects this view. For Heartflow to sustain this momentum, execution must match the raised guidance, and the company will need to demonstrate a credible path to full GAAP profitability—a milestone not yet reached but increasingly plausible given the current trend.